A Phase II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Biological Activity of Repeated doses of Autologous T Cells Transduced with VRX496 in HIV-Positive Subjects

Grants and Contracts Details

StatusFinished
Effective start/end date8/1/05 → 7/31/22

Funding

  • Virxsys Corporation: $49,474.00